Additionally, there is a growing body of evidence that Hh activation often occurs independently of its canonical receptors, which means that if Hh is to be targeted broadly in cancer therapy, there must be a focus on the Hh pathway downstream of Smo. The gene discussed is SMO; the disease is cancer.